GlassScriptPhysician profile
Steven Kurtin
NPI 1659364479
$5,902.57
in general payments reported to CMS, 2019-2025
23 companies · $561 in 2025
The $561 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $1,195 · 2021: $764 · 2022: $1,060 · 2023: $819 · 2024: $1,019 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,307 · Entertainment: $92.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.54 |
| Entertainment | $92.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $985.22 | 2019-2025 | Paragon Crt, Synergeyes Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $728.52 | 2021-2025 | Total30, Precision7 |
| The Walman Optical Company | $480.00 | 2020 | |
| Stryker Corporation | $427.14 | 2020 | |
| Bausch & Lomb Americas INC. | $386.07 | 2023-2024 | Infuse |
| Biotissue Holdings INC. | $323.15 | 2024 | |
| Lkc Technologies, INC. | $284.44 | 2023-2024 | |
| Optos, INC. | $274.48 | 2022-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $227.95 | 2022-2025 | |
| Dompe US, INC. | $225.36 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $225.02 | 2021 | |
| Abbvie INC. | $222.52 | 2022-2023 | |
| Abb Con-Cise Optical Group LLC | $198.27 | 2022 | |
| Sun Pharmaceutical Industries INC. | $193.38 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $156.44 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $127.47 | 2019 | |
| Genzyme Corporation | $122.03 | 2019 | |
| Eyevance Pharmaceuticals LLC | $121.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $114.51 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $47.92 | 2022 | |
| Allergan, INC. | $12.21 | 2019 | |
| Sight Sciences, INC. | $11.10 | 2020 | |
| Katena Products, INC. (Dba Corza Medical) | $7.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kurtin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.